Lung cancer where pY residues of EGFR have been exploited for treatment purpose in lung adenocarcinoma patients, but we do not have such kind of felicitously studied and catalogued data in ESCC patients. This evidence concerns the gene EGFR and esophageal squamous cell carcinoma.